Stallergenes Greer: nearly 120 years of combined expertise in allergy and allergen immunotherapy (AIT).
Established in 2015, Stallergenes Greer combines nearly 120 years of allergy expertise of Greer in the United States with Stallergenes’ history of innovation in allergy immunotherapy (AIT or desensitisation) from a base in France.
As a company 100% dedicated to the innovative treatment of allergies, Stallergenes Greer adopts a comprehensive approach to addressing and managing allergic diseases, offering allergy specialists an extensive range of products, from diagnosis to sublingual and subcutaneous allergen immunotherapy.
With a history of innovation, the company is at the origin of a new generation of allergy immunotherapy treatments. Upon its creation, Stallergenes Greer brought an essential contribution to allergy therapies at a time when symptomatic treatments were the gold standard. These efforts have considerably strengthened the level of evidence supporting allergy immunotherapy.
Allergen immunotherapy innovation has evolved significantly over the years. Stallergenes Greer has always endeavored to offer new treatment options to meet the needs of patients and to consolidate its knowledge and expertise in the field of innovative treatments with a view to developing products that seek to optimise treatment and management of patients with allergies. As the years have gone by, allergen immunotherapy innovation has evolved significantly.
Learn more about our approach to allergen immunotherapy.